Experimental immunotherapy of HIV has passed the first stage of testing security

Preliminary results of the first phase of clinical trials demonstrated the safety and tolerability of cell therapy, including the expression of T-cells ex vivo and subsequent injection of HIV-infected people who were previously treated by antiretroviral therapy. The study appeared September 21 in the journal Molecular Therapy.

“This study is devoted to finding ways of training the immune system to better battle with HIV,” says study author David Margolis from the University of North Carolina at chapel hill. “We found that this approach to retrain immune cells and their implementation was safe, which was the main purpose of the study. Data from this testing will help us develop improved treatments for HIV”.

Promising therapy for HIV

Antiretroviral therapy has transformed the doomed to death in the chronically ill. But this is not the final treatment, and the virus continues to hide from the immune system. Approaches with the use of pharmacological agents can cause latent virus to Express the viral protein that will make his tank vulnerable to T-cells. But existing HIV-driven immune responses in patients treated with ART people are not enough to overcome the disease even in the presence of agents that induce the expression of HIV.

One of the safest procedures call the T-cell responses to HIV is adoptive cell therapy. It involves collecting T cells from the patient, growing them in the laboratory to increase the number and return the patient to help the immune system fight disease. The first approaches with receiving T-cell therapy for HIV showed a low efficiency for various reasons. But since this area saw a lot of breakthroughs, mostly in the field of Oncology, and now this procedure can be not only safe, but highly effective.

Do you think scientists will one day defeat HIV? Tell us in our chat in Telegram.

Leave a Reply

Your email address will not be published. Required fields are marked *